Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
27
DARE Quote, Financials, Valuation and Earnings
Last price:
$2.47
Seasonality move
:
-22.86%
Day range:
$2.58 - $2.84
52-week range:
$2.11 - $9.19
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
854.30x
P/B ratio:
11.45x
Volume:
1.7M
Avg. volume:
2.9M
1-year change:
-22.94%
Market cap:
$23.2M
Revenue:
$9.8K
EPS (TTM):
-$0.18
Analysts' Opinion
-
Consensus RatingDare Bioscience has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.00, Dare Bioscience has an estimated upside of 396.18% from its current price of $2.62.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing -358.02% downside risk from its current price of $2.62.
Fair Value
-
According to the consensus of 3 analysts, Dare Bioscience has 396.18% upside to fair value with a price target of $13.00 per share.
DARE vs. S&P 500
-
Over the past 5 trading days, Dare Bioscience has overperformed the S&P 500 by 7.31% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Dare Bioscience does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Dare Bioscience has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Dare Bioscience reported revenues of $25.4K.
Earnings Growth
-
Dare Bioscience has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Dare Bioscience reported earnings per share of -$0.50.
Enterprise value:
12.9M
EV / Invested capital:
--
Price / LTM sales:
854.30x
EV / EBIT:
--
EV / Revenue:
496.28x
PEG ratio (5yr expected):
--
EV / Free cash flow:
2.14x
Price / Operating cash flow:
3.68x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-8.79%
Net Income Margin (TTM):
-6470.92%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-18016.75%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | $25.9K | $9.3K | $25.4K | |
| Gross Profit | -- | -- | -- | $1.6K | $25.4K | |
| Operating Income | -$31.4M | -$28.6M | -$22M | -$6M | -$4.6M | |
| EBITDA | -$31.3M | -$28.5M | -$21.8M | -$6M | -$4.4M | |
| Diluted EPS | -$4.26 | -$3.82 | -$0.18 | -$0.81 | -$0.50 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $9.6M | $47.8M | $29.5M | $10M | $11.8M | |
| Total Assets | $10.5M | $49.2M | $30.4M | $13M | $18.6M | |
| Current Liabilities | $6.1M | $16.4M | $24.3M | $17.7M | $21.2M | |
| Total Liabilities | $7.3M | $18.3M | $25.4M | $24M | $28.2M | |
| Total Equity | $3.3M | $30.9M | $5M | -$11M | -$9.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$21.9M | -$29.6M | $6.7M | -$6.8M | -$5.5M | |
| Cash From Investing | -$58.5K | -$636.7K | -$723.1K | -$7.3K | -$157.3K | |
| Cash From Financing | $2.6M | $14.4M | $666.4K | $14K | $246.6K | |
| Free Cash Flow | -$21.9M | -$30.2M | $6M | -$6.8M | -$5.6M | |
DARE
Sector
Market Cap
$23.2M
$34.4M
Price % of 52-Week High
28.51%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
-2.64%
-1.01%
1-Year Price Total Return
-22.94%
-37.36%
Beta (5-Year)
1.138
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.59
200-day SMA
Sell
Level
$3.13
Bollinger Bands (100)
Sell
Level
2.69 - 3.09
Chaikin Money Flow
Sell
Level
-108.1M
20-day SMA
Buy
Level
$2.59
Relative Strength Index (RSI14)
Sell
Level
47.88
ADX Line
Buy
Level
45.78
Williams %R
Buy
Level
-92.7966
50-day SMA
Sell
Level
$2.82
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Buy
Level
4
On Balance Volume
Neutral
Level
128.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-14.1972)
Sell
CA Score
(Annual)
Level (-8.8056)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (11.2229)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women’s health.
Stock Forecast FAQ
In the current month, DARE has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The DARE average analyst price target in the past 3 months is $13.00.
-
Where Will Dare Bioscience Stock Be In 1 Year?
According to analysts, the consensus estimate is that Dare Bioscience share price will rise to $13.00 per share over the next 12 months.
-
What Do Analysts Say About Dare Bioscience?
Analysts are divided on their view about Dare Bioscience share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Dare Bioscience is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Dare Bioscience's Price Target?
The price target for Dare Bioscience over the next 1-year time period is forecast to be $13.00 according to 3 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is DARE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Dare Bioscience is a Buy. 2 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DARE?
You can purchase shares of Dare Bioscience via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Dare Bioscience shares.
-
What Is The Dare Bioscience Share Price Today?
Dare Bioscience was last trading at $2.47 per share. This represents the most recent stock quote for Dare Bioscience. Yesterday, Dare Bioscience closed at $2.62 per share.
-
How To Buy Dare Bioscience Stock Online?
In order to purchase Dare Bioscience stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
